Home  >  Product Launches
Product Launches
+ Font Resize -

Ajanta Pharma introduces montelukast sodium oral granules in US market

Our Bureau, Mumbai
Tuesday, November 17, 2015, 12:45 Hrs  [IST]

Ajanta Pharma Limited, a Rs. 1,450 crore plus Mumbai-based fully-integrated pharmaceutical company, announced that its subsidiary Ajanta Pharma USA Inc has introduced montelukast sodium oral granules (4mg), a bioequivalent generic version of Merck's Singulair granules, in the US market.

Ajanta Pharma offers montelukast granules in cartons containing 30 individual sachets.

The approval and launch of the montelukast granules is part of an ever-growing portfolio that Ajanta Pharma has developed for the US market.

To date, the United States Food & Drug Administration (FDA) has granted five ANDA final approvals and two ANDA tentative approvals. An additional 19 ANDAs are pending approval from the US FDA.

 

Post Your commentsPOST YOUR COMMENT
Comments
* Name :     
* Email :    
  Website :  
   
     
 
Chemspec_India-2018
CPHI18_banner_150x6
CPhI_Japan_150x60_2018
DIRQ_150x60_2018
Pharmabiz: PPM_150x60_2018
CPHI-SEA-2018-150x60-Register-Now-STAT-English-v1
MTWCbanners_150X60_08
VF118_Banner_150x60_E_D2
duphat_150x60
IPJPI18_150x60en_2018
 
 
 
 
Copyright © 2016 Saffron Media Pvt. Ltd |